Treatment failure in invasive aspergillosis: susceptibility of deep tissue isolates following treatment with amphotericin B
- PMID: 14519673
- DOI: 10.1093/jac/dkg434
Treatment failure in invasive aspergillosis: susceptibility of deep tissue isolates following treatment with amphotericin B
Abstract
Objectives: To determine whether treatment failure in invasive aspergillosis (IA) is the result of resistance of Aspergillus spp. isolates to amphotericin B.
Methods: Six Aspergillus fumigatus and six Aspergillus flavus isolates cultured from deep tissue biopsies in 11 patients with haematological malignancies during 1991-1998 were tested. A method based on the NCCLS M38-A broth microdilution method, with colorimetric determination of MICs, was used to determine the MICs of amphotericin B and itraconazole.
Results: All A. fumigatus isolates were susceptible to amphotericin B (MIC 0.25-0.5 mg/L), as were three A. flavus isolates (MIC 1 mg/L), but three were less susceptible (MIC 2 mg/L). All isolates were susceptible to itraconazole (MIC 0.125-0.25 mg/L). All patients had been treated with amphotericin B, having received a median of 12 days of treatment when the tissue was obtained.
Conclusion: The difficulty in treating IA may not be because of the susceptibility of the isolates, but because of poor penetration of antifungal agents into infected tissue. Aspergillus spp. invade blood vessels causing thrombosis and tissue infarction, and therefore it may be difficult for antifungal drugs to exceed MICs in infected tissues. This highlights the need for different treatment strategies, such as surgery and the administration of cytokines.
Similar articles
-
Comparison of the Sensititre YeastOne colorimetric antifungal panel and Etest with the NCCLS M38-A method to determine the activity of amphotericin B and itraconazole against clinical isolates of Aspergillus spp.J Antimicrob Chemother. 2003 Sep;52(3):365-70. doi: 10.1093/jac/dkg384. Epub 2003 Aug 13. J Antimicrob Chemother. 2003. PMID: 12917236
-
In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole.Mycoses. 2007 Nov;50(6):447-50. doi: 10.1111/j.1439-0507.2007.01409.x. Mycoses. 2007. PMID: 17944704
-
Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B.J Antimicrob Chemother. 2003 Apr;51(4):913-9. doi: 10.1093/jac/dkg185. Epub 2003 Mar 13. J Antimicrob Chemother. 2003. PMID: 12654746
-
Update on antifungal drug resistance mechanisms of Aspergillus fumigatus.Drug Resist Updat. 2005 Dec;8(6):344-58. doi: 10.1016/j.drup.2006.01.001. Epub 2006 Feb 20. Drug Resist Updat. 2005. PMID: 16488654 Review.
-
[Curative treatment of invasive aspergillosis].Pathol Biol (Paris). 1994 Sep;42(7):688-93. Pathol Biol (Paris). 1994. PMID: 7877863 Review. French.
Cited by
-
Fungal biofilm architecture produces hypoxic microenvironments that drive antifungal resistance.Proc Natl Acad Sci U S A. 2020 Sep 8;117(36):22473-22483. doi: 10.1073/pnas.2003700117. Epub 2020 Aug 26. Proc Natl Acad Sci U S A. 2020. PMID: 32848055 Free PMC article.
-
Invasive Aspergillosis in the Intensive Care Unit.Diagnostics (Basel). 2022 Nov 6;12(11):2712. doi: 10.3390/diagnostics12112712. Diagnostics (Basel). 2022. PMID: 36359555 Free PMC article. Review.
-
Aspergillus infections in transplant recipients.Clin Microbiol Rev. 2005 Jan;18(1):44-69. doi: 10.1128/CMR.18.1.44-69.2005. Clin Microbiol Rev. 2005. PMID: 15653818 Free PMC article. Review.
-
Susceptibility breakpoints for amphotericin B and Aspergillus species in an in vitro pharmacokinetic-pharmacodynamic model simulating free-drug concentrations in human serum.Antimicrob Agents Chemother. 2014;58(4):2356-62. doi: 10.1128/AAC.02661-13. Epub 2014 Feb 10. Antimicrob Agents Chemother. 2014. PMID: 24514094 Free PMC article.
-
Filamentous fungal biofilms: Conserved and unique aspects of extracellular matrix composition, mechanisms of drug resistance and regulatory networks in Aspergillus fumigatus.NPJ Biofilms Microbiomes. 2022 Oct 19;8(1):83. doi: 10.1038/s41522-022-00347-3. NPJ Biofilms Microbiomes. 2022. PMID: 36261442 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous